Is Indivior (INDV) overvalued or fairly valued?

MarketChacha shows Indivior's valuation in context — a trailing P/E of about 26.2, a forward P/E of about 9.7 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Indivior's revenue?

Indivior reported revenue of $1.2B for FY2025, with net profit of $210.0M, per official filings.

What is the share price of Indivior (INDV)?

Indivior last traded at $40.36 (-0.2% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

Indivior

INDV · NYSE · Healthcare · United States

$40.36-0.2%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 7:29 PM

Snapshot

TickerINDV

ExchangeNYSE

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

CountryUnited States

Employees827

HeadquartersNorth Chesterfield, United States

Market cap$4.8B

P/E (TTM)26.2

Volume419.98K

Websitewww.indivior.com

Filings tracked4

About Indivior

Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Profile as reported by Yahoo Finance.

Who owns it

Insiders2.0%
Institutions98.0%
Public & other0.0%

397 institutional holders

As reported by Yahoo Finance.

Top holders

Blackrock Inc.15.21%
Vanguard Portfolio Management LLC6.47%
Oaktree Capital Management LP5.73%
Vanguard Capital Management LLC4.58%
State Street Corporation4.02%
Two Seas Capital Lp3.89%
Millennium Management Llc3.77%
Fuller & Thaler Asset Management Inc.3.72%

Largest institutional holders, as reported by Yahoo Finance (as of 3/31/2026).

Forensic scorecard

Over 3 years only -3.20× of reported profit became operating cash — the classic sign that headline earnings may be running ahead of the cash actually generated. Often explained by working capital funding growth; worth a closer look.

Cash conversion-3.20×

Net margin trend-11.5% → 16.9%

Margin has expanded by about 28.5 points — the business is getting more profitable.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $315.0M · EPS 0.98

Est. earnings growth +36.2%

Next fiscal year

Rev $1.3B · EPS 4.17

Est. earnings growth +8.1%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

$16.1352-wk range$42.81

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Market cap

$4.8B

Day change

-0.2%

P/E (TTM)

26.2

Fwd P/E

9.7

Beta

1.15

Revenue (FY2025)

$1.2B

Net margin

16.9%

Revenue CAGR (2y)

+6.5%

EPS (FY2025)

1.64

Net profit (FY2025)

$210.0M

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about INDV

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin
FY2025	$1.2B	$210.0M	1.64	16.9%
FY2024	$1.2B	$7.0M	0.05	0.6%
FY2023	$1.1B	$-126.0M	-0.92	-11.5%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q1	$317.0M	$89.0M	0.69	28.1%
2025Q3	$314.0M	$42.0M	0.33	13.4%
2025Q2	$302.0M	$18.0M	0.14	6.0%
2025Q1	$266.0M	$47.0M	0.38	17.7%
2024Q4	—	$21.0M	—	—
2024Q3	$307.0M	$22.0M	0.16	7.2%
2024Q2	$299.0M	$-97.0M	-0.72	-32.4%
2024Q1	$284.0M	$61.0M	0.45	21.5%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Executive/director change, Shareholder vote results
SEC5/15/2026material
8-K — Reg FD disclosure, Other events, Exhibits
SEC5/4/2026material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC4/30/2026material
10-Q filing
SEC4/30/2026

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.